Quetiapine versus other atypical antipsychotics for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 11, 2013, Pages

  Asmal, Laila ^a   Flegar, Srnka J ^a   Wang, Jikun ^b   Rummel Kluge, Christine ^c   Komossa, Katja ^d   Leucht, Stefan ^e  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b EAST CHINA NORMAL UNIVERSITY   (China)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; CLOZAPINE; GLUCOSE; OLANZAPINE; PALIPERIDONE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; BODY WEIGHT CHANGE; BODY WEIGHT GAIN; CENTRAL NERVOUS SYSTEM; COMPARATIVE EFFECTIVENESS; DIET RESTRICTION; DRUG FATALITY; DRUG SAFETY; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEART DISEASE; HEMATOLOGIC DISEASE; HOSPITAL READMISSION; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; METABOLIC DISORDER; MULTICENTER STUDY (TOPIC); NEGATIVE SYNDROME; NEUROLOGIC DISEASE; POSITIVE SYNDROME; PRIORITY JOURNAL; QT PROLONGATION; QTC PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SENSITIVITY ANALYSIS; SIMPSON-ANGUS SCALE; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; MEDICATION COMPLIANCE; META ANALYSIS; STATISTICS;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIBENZOTHIAZEPINES; HUMANS; MEDICATION ADHERENCE; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA; THIAZOLES;

EID: 84900782041     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006625.pub3     Document Type: Review

References (348)

1. Astrazeneca 1998. A multicentre, double-blind randomised comparison of seroquel (TM) and risperidone in the treatment of schizophrenic patients with acute exacerbation. Astrazeneca trial data.
2. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Journal of Clinical Psychiatry 2003;64(5):598-604.
3. Byerly MJ, Nakonezny PA, Rush AJ. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial. Psychiatry Research 2008;159:115-20.
4. Canuso C, Carothers J, Dirks B, Zhu Y, Kosik-Gonzalez C. A double-blind, placebo-controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the American Psychiatric Association 161st Annual Meeting, Washington, DC, May 3-6, 2008.
5. Canuso C, Dirks B, Carothers J, Zhu Y, Kosik-Gonzalez C. A comparative analysis of paliperidone ER and quetiapine in patients with a recent, acute exacerbation of schizophrenia. Schizophrenia Research 2008;98:158-9.
6. Canuso C, Dirks B, Carothers J, Zhu Y, Kosik-Gonzalez C. A double-blind, placebo controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, February 3-7, 2007.
7. Canuso C, Dirks B, Carothers J, Zhu Y, Kosik-Gonzalez C. A double-blind, placebo-controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 20th Annual U.S. Psychiatric & Mental Health Congress, Orlando, FL, October 11-14, 2007.
8. Canuso CM, Dirks B, Carothers ScD, Kosik-Gonzalez C, Bossie CA, Zhu Y, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. American Journal of Psychiatry 2009;AiA:1-11.
9. Conley RR, Kelly DL, Nelson MW, Richardson CM, Feldman S, Benham R, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clinical Neuropharmacology 2005;28(4):163-8.
10. Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 2006;31(3):340-6.
11. Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Journal of Clinical Psychiatry 2005;66:80-4.
12. Richardson CM, Kelly DL, Gold JM, McMahon R, Yu Y, Conley RR. Risperidone vs quetiapine vs fluphenazine in treatment-resistant schizophrenia: neuropsychological outcome. Schizophrenia Bulletin 2005;31:501-2.
13. Deberdt W, Lipkovich I, Heinloth AN, Liu L, Kollack-Walker S, Edwards SE, et al. Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. Therapeutics and Clinical Risk Management 2008;4(4):713-20.
14. Eerdekens M, Kramer M, Cleton A, Vanderbosch A, Natarajan J, Earnest J, et al. Proceedings of the 20th European College of Neuropsychopharmacology, Vienna, Austria, October 13-17, 2007.
15. Hough DW, Natarajan J, Vandebosch A, Rossenu S, Kramer M, Eerdekens M. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. International Clinical Psychopharmacology 2010;0(0):1-10.
16. Hatta K, Sato K, Hamakawa H, Takebayashi H, Kimura N, Ochi S, et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophrenia Research 2009;113:49-55.
17. Hu GH, Wu YJ, Li QX. A comparative study between quetiapine and risperidone in the treatment of first-episode schizophrenia. Chinese Medical Journal of Metallurgical Industry 2008;25(1):16-7.
18. Kinon BJ, Liu-Siefert H, Hill AL, Roychowdhury S, Edwards SB. Superiority of olanzapine versus quetiapine in improving overall functioning in patients with schizophrenia. Proceedings of the 16th European College of Neuropsychopharmacology Congress, September 20-24, 2003.
19. Kinon BJ, Noordsy DL, Liu-Seifert H, Gulliver AH, Ascher-Svanum H, Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. Journal of Clinical Psychopharmacology 2006;26(5):453-61.
20. Li Y, Wang CH, Zhang DH, Wang LH, Zhao Z. A study of quetiapine and clozapine in treatment of first-episode schizophrenia. Chinese Journal of Nervous and Mental Diseases 2002;28:219-20.
21. Li CH. A study of quetiapine and clozapine in treatment of schizophrenia. Chinese Journal of Nervous and Mental Diseases 2003;29:306-7.
22. Li Y, Feng YG. A double blind comparing study between the effects of quetiapine and clozapine on the life quality of the patients with schizophrenia. Medical Journal of Chinese Peoples Health 2005;17:262-4.
23. * Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353(12):1209-23.
24. Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM, et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry 2009;31:1-9.
25. Daumit GL, GoffDC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research 2008;105:178-87.
26. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry 2007;64:633-47.
27. Keefe RSE, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry 2007;164:1061-71.
28. Meyer JM, Davis VG, McEvoy JP, GoffDC, Nasrallah HA, Davis SM, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research 2008;103:104-9.
29. Meyer JM, McEvoy JP, Davis VG, GoffDC, Nasrallah HA, Davis SM, et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry 2006;66:1013-22.
30. Meyer JM, Nasrallah HA, McEvoy JP, GoffDC, Davis SM, Chakos M, et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research 2005;80:9-18.
31. Miller DD, CaroffSN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. The British Journal of Psychiatry 2008;193:279-88.
32. Miller DD, McEvoy JP, Davis SM, CaroffSN, Saltz BL, Chakos MH, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research 2005;80:33-43.
33. Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin 2009;35(2):336-46.
34. Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RSE. Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry 2008;165:978-87.
35. Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum 2006;11(7 Suppl 7):32-9.
36. Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research 2009;111:9-16.
37. Penn DL, Keefe RSE, Davis SM, Meyer PS, Perkins DO, Losardo D, et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research 2009;115:17-23.
38. Perkins DO, Gu H, Weiden PJ, McEVoy JP, Hamer RM, Lieberman JA. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69(1):106-13.
39. Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA. Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research 2010;116:118-25.
40. Resnick SG, Rosenheck RA, Canive JM, Souza CD, Stroup TS, McEvoy J, et al. Employment outcomes in a randomised trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research 2008;35(2):215-25.
41. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, et al. Data from the CATIE Trial. Schizophrenia Research 2009;107:22-9.
42. Rosenheck RA, Davis VG, Davis SM, Stroup S, McEvoy J, Swartz M, et al. The CATIE schizophrenia trial. Schizophrenia Research 2009;113:12-8.
43. Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, et al. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research 2005;80:1-8.
44. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RSE, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research 2009;107:1-12.
45. Swanson JW, Swartz MS, van Dorn RA, Volavka J, Monahan J, Stroup TS, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry 2008;193:37-43.
46. Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry 2007;164:428-36.
47. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RSE, et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services 2008;59(5):500-6.
48. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research 2008;100:39-52.
49. Liu Y, Xu M, Chen X. A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms. Shandong Archires of Psychiatry 2004;17(1):6-8.
50. Lu X, Cheng H, Song S, Sun L, Zhang Y, Fan Y. A study of quetiapine and risperidone and clozapine in the treatment of schizophrenia. China and Foreign Medical Journal 2006;4(6):62-4.
51. Luo X, An BF. Comperison of quetiapine and aripiprazole in the treatment of first episode schizophrenia. Journal of Clinical Psychological Medicine 2008;18(3):191-2.
52. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 2006;163(4):600-10.
53. Keefe R, Gu H, Sweeney J, Perkins D, McEvoy J, Hamer R, Lieberman J. A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis. Proceedings of the 44th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 11-15, 2005.
54. Keefe RSE, Gu H, Sweeney JA, Perkins DO, McEvoy JP, Hamer RM, Lieberman JA. The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first-episode psychosis: a double-blind 52-week comparison. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25, 2006.
55. Keefe RSE, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry 2007;164:1061-71.
56. Lieberman J, McEvoy JP, Perkins D, Hamer RH. Comparison of atypicals in first-episode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone. Journal of the European College of Neuropsychopharmacology 2005;15(Suppl 3):S525.
57. McEvoy JP. Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, May 20-25, 2006, Toronto, Canada.
58. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry 2007;164:1050-60.
59. McEvoy JP, Perkins DO, Gu H, Hamer RM, Lieberman JA. Clinical effectiveness and predictors of treatment non-adherence: comparison of olanzapine, quetiapine, and risperidone in first-episode psychosis. Schizophrenia Research 2006;86(Suppl 1):S130.
60. Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophrenia Research 2009;111:9-16.
61. Perkins DO, Gu H, Weiden PJ, McEVoy JP, Hamer RM, Lieberman JA. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69(1):106-13.
62. Mori K, Nagao M, Yamashita H, Morinobu S, Yamawaki S. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004;28(4):659-65.
63. Ozguven Hd, Oner O, Baskak B, Oner P, Atbasoglu EC. The metabolic and clinical effects of olanzapine and quetiapine: preliminary findings from a randomized single-blind trial in patients with schizophrenia. Schizophrenia Research 2004;67(1):190-1.
64. Peng X, Huang Y, Liu XY. A clinical analysis of aripiprazole and quetiapine in treatment of first episode schizophrenia. Journal of Clinical Psychological Medicine 2007;17(5):329-30.
65. Gharabawi GM, Greenspan A, Rupnow MFT, Kosik-Gonzalez C, Bossie CA, Zhu Y, et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry 2006;6(45):1-7.
66. Greenspan A, Kosik-Gonzalez C, Moreau-Mallet V, Bossie CA, Rupnow MFT, Zhu Y, Gharabawi GM. Risperidone vs quetiapine in inpatients with schizophrenia: a double-blind placebo-controlled study. Journal of the European College of Neuropsychopharmacology 2005;15(Suppl 3):S503.
67. Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MFT, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research 2006;85(1-3):254-65.
68. Potkin SG, Greenspan A, Kosik-Gonzalez C, Bossie C, Rupnow M, Zhu Y, et al. A placebo-controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin 2005;31:501.
69. Riedel M, Muller N, Strassnig M, Spellmann I, Engel RR, Musil R, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience 2005;255(6):432-7.
70. Riedel M, Spellmann I, Muller N, Strassnig M, Muller-Arends A, Dehning S, Moller HJ. Cognitive benefits of quetiapine versus risperidone in schizophrenia. Proceedings of the 158th Annual Meeting of the American Psychiatric Association, Atlanta GA, USA, May 21-26, 2005.
71. Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience 2007;257:360-70.
72. Riedel M, Müller N, Spellmann I, Engel RR, Musil R, Valdevit R, et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions with an acute episode of schizophrenia. European Archieves of Psychiatry and Clinical Neuroscience 2007;257(7):402-12.
73. Sacchetti E, Valsecchi P, Regini C, Galluzo a, Cacciani P, Agrimi E, Mencacci C. Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study. Schizophrenia Research 2004;67(1):150.
74. Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P. Comparison of quetiapine, olanzapine and risperidone in a randomized study in patients with schizophrenia. Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update", Florence, Italy, November 10-13, 2004.
75. Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P, Agrimi E, Mencacci C. Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study. Journal of the European College of Neuropsychopharmacology 2003;13(4):S350.
76. Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P, Agrimi E, Mencacci C. Comparison of quetiapine, olanzapine, and risperidone in schizophrenia. Journal of the European College of Neuropsychopharmacology 2004;14(Suppl 3):S286.
77. Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P, Agrimi E, et al. Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study. Proceedings of the 16th European College of Neuropsychopharmacology Congress, Prague, Czech Republic, September 20-24, 2003.
78. Sirota P, Pannet I, Koren A, Tchernichovsky E. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Human Psychopharmacology 2006;21(4):227-34.
79. Sirota P, Tchernichowsky E, Panet I, Koren A. The effectiveness of quetiapine versus olanzapine in improving negative symptoms of patients with schizophrenia. Schizophrenia Research 2004;67(1):170.
80. Song GM, Li JH, Zhong H, Lu SL. Control study of risperidone oral solution and quetiapine on schizophrenia. Modern Journal of Integrated Traditional Chinese and Western Medicine 2008;17(32):4961-3.
81. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 2006;163(4):611-22.
82. Svestka J, Synek O, Zourkova A. A double-blind comparison of olanzapine and quetiapine in treatment of acute exacerbations of schizophrenic or schizoaffective disorders. Journal of the European College of Neuropsychopharmacology 2003;13(4):S291.
83. Voruganti LP, Awad AG, Parker G, Forrest C, Usmani Y, Fernando MLD, et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research 2007; Vol. 96, issue 1:146-55.
84. Wang DF, Wang XR. A control study of quetiapine and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2006;35(18):1697-8.
85. Wei QW, Fang YR, Shen XL, Tian T, Liao JG, Fang XG. A comparative study of social function in first-episode schizophrenic patients treated with quetiapine and risperidone. Shandong Archives of Psychiatry 2006;19(1):34-6.
86. Wei SZ, Tang QS, Xu ZN, Rang XJ, Lu B. Dummy parallel controlled study in the female first-episode schizophrenia treated with aripiprazole and quetiapine. Chinese Journal of Nervous and Mental Disorders 2006;32(6):511-7.
87. Harvey PD, Patterson TL, Potter LS, Zhong K, Brecher M. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. American Journal of Psychiatry 2006;163(11):1918-25.
88. Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. Journal of Clinical Psychiatry 2006;67(7):1093-103.
89. An BF, Liu XQ, Chen JX. A comparative study between quetiapine and clozapine in the treatment of schizophrenia and the relation with the plasman levels of IL-2, SIL-2R. Schuan Mental Health 2003;16(3):152-4.
90. An BF, Zhang ML, Qi SG. Comparitive study between the effect olanzapine and quetiapine in first-episode schizophrenia. Journal of Clinical Psychological Medicine 2006;16(2):84-5.
91. An BF, Li Y, Wang CH. A study on the executive function of first episode paranoid schizophrenia. Chinese Journal of Behavioral Medical Science 2006;15(4):340-1.
92. Antonova E, Kumari V, Halari R, Zachariah E, Mehrotra R, Kumar A, et al. Superior cognitive efficacy of atypical antipsychotics olanzapine, risperidone, and quetiapine, as a group, relative to low doses of conventional antipsychotics. Schizophrenia Bulletin 2005;31:474.
93. Arango C, Robles O, Parellada M, Fraguas D, Sancho-Ruiz A, Medina O, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 2009;18:418-28.
94. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006;6(8):1-16.
95. Baloescu A, Vasile D, Gheorghe MD, Grigorescu G. Side effects of atypical antipsychoticsprediction factor for compliance. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S403.
96. Ban N, Cui JB. Analysis of the efficacy of aripiprazole and quetiapine in the treatment of schizophrenia. Occupation and Health 2008;24(3):292-3.
97. Beuzen J-N, Pans M, Modell S, Hagens P, McQuade R, Iwamoto T, et al. Naturalistic study of aripiprazole treatment. Proceedings of the XIII World Congress of Psychiatry, Cairo, Egypt, September 10-15, 2005.
98. Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, Kahn RS. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophrenia Research 2009;115:97-103.
99. Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, et al. Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. Schizophrenia Research 2009;115:104-14.
100. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-97.
101. Brecher M, Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, et al. Differential effects of quetiapine, olanzapine and risperidone on glucose metabolism: a 24-week study in schizophrenia. International Congress on Schizophrenia Research. 2007.
102. Byerly M, Weber M. Clozapine versus quetiapine for schizophrenia. Stanley Foundation Research Programs 1999.
103. Byerly MJ, Nakonezny P, Bugno R, Boles J. A randomized, double-blind pilot trial of switching to quetiapine vs. risperidone continuation in outpatients with risperidone-associated sexual dysfunction. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25, 2006.
104. Cai QQ, Wang ZW, Lin YC, Wang XY. A control study of quetiapine and clozapine in the treatment of schizophrenia. The Medicine Magazine of China 2005;3(8):465-6.
105. Canas F, Perez V, Tafalla M. Quetiapine and risperidone in the treatment of schizophrenia: a short- and long-term, non-randomized study. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25, 2006.
106. Cao D, Xie S-P, Chen Q-B, Yuan Y-G, Fang Q. Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia. Chinese Journal of Clinical Rehabilitation 2005;9(36):63-8.
107. Cao D, Xie S-P, Chen Q-B, Yuan Y-G, Fang Q. Comparison of the effects of chlorpromazine, risperidone and quetiapine on hypothalamic-pituitary-gonadal axis and sexual function in male patients with schizophrenia. Chinese Journal of Clinical Rehabilitation 2005;9(20):148-51.
108. Cao D, Xie SP, Chen QB, Yuan YG, Fang Q. Effects of antipsychotic on pituitary-gonadal axis in male patients with schizophrenia. Journal of Clinical Psychological Medicine 2006;16(4):209-11.
109. Cao CA, Guo JH, Gao H. Comparison of curative effect and safety of quetiapine and risperidone in the treatment of female schizophrenia. Medical Journal of Chinese People's Health 2006;18(6):433-4.
110. Chang GS, Li J. A control study of quetiapine and risperidone in the treatment of schizophrenia. China Practice Medicine 2007;2(34):52-3.
111. Chang YS, Gu YS. A control study of quetiapine and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2008;20(17):2010-1.
112. Chaudhry HR, Niaz S, Arshad N, Peracha F, Ayub A, Mufti KA. Comparison of risperidone, olanzapine and quetiapine in relation to body weight, serum blood glucose and prolactin levels. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S241.
113. Chen ZE, Liu HR, Wu SQ. A control study of quetiapine and risperidone in the treatment of female schizophrenia. Herald of Medicine 2006;25(6):548-50.
114. Chen RY, Luo RQ, Wang AQ, Mei HB. A study of quetiapine on the quality of life of elderly schizophrenia. Medical Journal of Chinese People's Health 2006;18(6):447-8.
115. Chen JG. Control study on management of first-episode schizophrenia with risperidone and quetiapine. China Pharmaceuticals 2007;16(9):43-4.
116. Chen FX. A control study of quetiapine vs risperidone in first-episode schizophrenia. Jiangxi Medicine 2007;42(10):917-8.
117. Chen F, Wang HY, Li DY, Zhou BW, Chen FY. A control study of quetiapine and aripiprazole in the treatment of female first-episode schizophrenia. Journal of Psychiatry 2007;20(6):381-3.
118. Chen HB, Fu F, Yang QJ. A control study of quetiapine and risperidone in the treatment of schizophrenia. Medical Information 2008;21(3):389-90.
119. Chu JP. Comparative study of quetiapine and risperidone in the treatment of late onset schizophrenias. Journal of Clinical Psychological Medicine 2006;16(1):34-5.
120. Cortese L, Caligiuri MP, Williams R, Schieldrop P, Manchanda R, Malla A, Harricharan R. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol 2008;28:69-73.
121. Dai J-P, Zhao Z-H, Mai G-Y. Comparative study on the effect of olanzapine and seroquel of schizophrenia. Chinese Journal of Behavioral Medical Science 2004;13(3):291-3.
122. Dai J-P, Zhao Z-H, Liu G-X. Comparison of efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia. Chinese Journal of Behavioral Medical Sience 2005;14(8):712-14.
123. Dai XG, Xia XL, Ye XR. The effects of seroquel and risperidone on serum prolactin levels of female schizophrenia. Chinese Journal of Modern Drug Application 2008;2(3):10-1.
124. Davies LM, Lewis S, Jones PB, Barnes TRE, Gaughran F, Hayhurst D, et al. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Value in Health 2008;11(4):549-62.
125. Ding Y, An B, Li G, Li Y. A comparative study of risperidone and quetiapine in the treatment of schizophrenia and relationship between efficacy and the serum levels of il-2?sil-2r. Shandong Archives of Psychiatry 2004;17(2):76-8.
126. Dong W, Yang X. A control study of quetiapine and ziprasidone in the treatment of first-episode schizophrenia. Medical Journal of Chinese People's Health 2008;20(12):1275-6.
127. Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study. Journal of Clinical Psychiatry 2005;66:1021-30.
128. Feng D-J, Zhou T, Xiong L-H, Thian D-F. A study of quetiapine and clozapine in treatment of chronic schizophrenia. Journal of Luzhou Medical College 2003;26(6):511-12.
129. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. International Journal of Neuropsychopharmacology 2005;8(2):175-82.
130. Fan J-H, Li W-J. A study of quetiapine in treatment of negative symptoms dominant schizophrenia. Sichuan Mental Health 2005;18:178.
131. Fan BF, Chen CF, Xu Y, Cao PL, Gao P. The effects of quetiapine, risperidone and clozapine for schizophrenia on serum prolactin level. Chinese Medical Journal of Metallurgical Industry 2008;25(1):14-5.
132. Fleischhacker WW, Keet IPM, Kahn RS. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophrenia Research 2005;78(2-3):147-56.
133. Fu H, Yu H, Huo J. A comparative study of quetiapine vs clozapine in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases 2005;11(4):313-4.
134. Fu H, Yu H, Huo J. A comparative study of quetiapine vs clozapine in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases 2005;11(4):313-4.
135. Gao CZ, Gao Z. A study of quetiapine in the treatment of first-onset schizophrenia. Journal of Clinical Psychological Medicine 2003;13(4):221-2.
136. García MC, Vidal M, Ramos R. Sexual side effects of antipsychotics and treatment adherence. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S378.
137. Guo ZY, Liu JM, Yang JZ, Guo H, Wang AQ. Efficacy quetiapine in the treatment of schizophrenic patients and effect on the quality of life. China Journal of Health Psychology 2008;16(5):544-6.
138. Hao H. A control study of quetiapine and seroquel in the treatment of schizophrenia. Journal of Medical Forum 2007;28(15):60-1.
139. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, et al. A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition. Journal of Clinical Psychopharmacology 2004;24(1):62-9.
140. He J, Chen YX. A controlled study on quetiapine and clozapine in the treatment of schizophrenic patients. Medical Journal of Chinese Civil Administration 2003;15(6):335-6.
141. Horacek J, Seifertova D, Janu L, Petranova T. The effect of quetiapine on different domains of cognition and negative symptoms in schizophrenia. Proceedings of the Biennial Winter Workshop on Schizophrenia, February 7-13, 2004.
142. Huang S-P, Ma Z-W, Guo B-Y. Effectiveness of quetiapine vs clozapine in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases 2003;9(4):206-7.
143. Huang X, Liu JY. Effects of clozapine and seroquel on the glucose metabolism in schizophrenic patients. Jiangxi Medicine 2006;41(5):264-6.
144. Huber TJ, Borsutzky M, Schneider U, Emrich HM. Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis. Acta Psychiatrica Scandinavica 2004;109(4):269-74.
145. Jiang ZX, He XY, He XC, Li LW, Peng ZE. A control study of quetiapine and aripiprozole in the treatment of schizophrenia. Journal of Clinical Research 2006;23(8):1327-8.
146. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002;162:3-10.
147. Keks NA, Tonso M, Tabone K, McHugh M, Thomas R, Tune P, Gelman M. Clinical experience with atypical antipsychotics in acute inpatient unit: focus on quetiapine. International Journal of Psychiatry in Clinical Practice 2006;10(2):1-4.
148. Kelemen O, Nagy O, Máttyássy A, Kiss I, Janka Z, Kéri S. Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S430.
149. Kim JG, Cho DH, Choi HK, Kim HJ, Cho JH, Kang SH, et al. The comparison of risperidone, olanzapine and quetiapine in the treatment of chronic schizophrenia and schizoaffective disorder. Journal of the European College of Neuropsychopharmacology 2004;14(Suppl 3):S245.
150. Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. Journal of Clinical Psychopharmacology 2004;24(1):56-61.
151. Kolotkin RL, Corey-Lisle PK, Crosby RD, Kan HJ, McQuade RD. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. European Psychiatry 2008;23:561-6.
152. Koponen. Study in Schizophrenic In-Patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose. Clinical Trial Registration Data 2008.
153. Kuang YH, Zhao L. A comparative study on the efficacy and weight gain between quetiapine and clozapine in the treatment of schizophrenia. Journal of Psychiatry 2007;20(4):217-8.
154. L'Italien G, Hanssens L, Kan HJ, Baker RA, Marcus RN, McQuade RD, et al. Metabolic effects of aripiprazole versus olanzapine, quetiapine, or risperidone (the Star trial). Proceedings of the 11th International Congress on Schizophrenia Research, Colorado Springs, Colorado, USA, March 28-April 1, 2007.
155. Lan GX, Li ZC, Liu R, Deng G, Wu YM, Xie GP. A control study of quetiapine and clozapine in the treatment of schizophrenia. Journal of Ganna Medical University 2006;26(6):850-2.
156. Li HF, Gu NF, Xie B, Li M, Zhang L, Cheng Y, Wang MJ. Quetiapine in treatment of schizophrenia: a randomized, controlled, multicentre study. Chinese Journal of New Drugs and Clinical Remedies 2001;20(4):260-3.
157. Li DG, Zheng MX, Zheng JJ. A comparative study between quetiapine and clozapine in the treatment of schizophrenia. Jiuheyuan Hospital of Shishou 2002;12(5):267-8.
158. Li CM. A comparison of cognitive function in the first-onset schizophrenia treated with quetiapine and clozapine. Medical Journal of Chinese People Health 2003;15(12):718-21.
159. Li X, Lao G, Cao L. Comparison of efficacy and safety of seroquel and resperidone in the treatment of schizophrenia. Chinese Journal of Behavioral Medical Science 2003;12(1):45-6.
160. Li H. A controlled study of schizophrenia treated with quetiapine and clozapine. Chinese Modern Medical and Clinical 2005;3(7):33-4.
161. Li G, Chen Q-G, Zhang Q-H. A comparison analysis on the efficacy of quetiapine and risperidone in cognitive function of schizophrenia. Chinese Journal of Behavioral Medical Science 2005;14(11):1007-8, 1036.
162. Li M, Lv W, Xing X. A control study of quetiapine and aripiprazole in the treatment of schizophrenia. Chinese Journal of Postgraduate Medicine 2007;30(11):49-50.
163. Li Q, Wang W, Chen C, Li YM. Comparison of efficacy and safety of seroquel and risperidone in the treatment of schizophrenia. Huaxi Pharmacy 2007;22(3):354-5.
164. Li G, Zuo J, Chen Q, Zhou H. A comparison analysis on the efficacy of quetiapine and risperidone in the treatment of schizophrenia. Tianjin Pharmacy 2008;20(1):42-4.
165. Li S. A control study of quetiapine and olanzapine in the treatment of schizophrenia. Journal of Nongken Medicine 2008;30(1):31-3.
166. Li W. Influence on the psychopathology and the quality of life of schizophrenia treated with risperidone, clozapine and quetiapine. Medical Information 2008;21(12):2253-5.
167. Li DM. The cross-check analysis of risperdal and quetiapine alleviating negative symptoms of schizophrenia. Laboratory Medicine and Clinic 2008;5(19):1162-3.
168. Liang L, Wang D, Shen Y. Influence of quetiapine and clozapine on fasting blood glucose of first-episode schizophrenia. Practical Pharmacy and Clinical Remedies 2008;11(5):296-7.
169. Lin Z. Analysis of therapeutic effect of quetiapine on schizophrenia patient. China Tropical Medicine 2005;5(6):1299.
170. Lin H, Wang J. A study of quetiapine in the treatment of elderly schizophrenia. Qinghai Pharmacy 2007;37(4):67-8.
171. Liu X, Lin L, Fan Y, Dong X. A comparative study of new anti-psychopathic drugs lead to gain weight. Medical Journal of Chinese People's Health 2003;15(4):230-1.
172. Liu K, Wang X, Jiang L, Geng H, Cng X, Shi L, Zhao H. A control study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Hebei Mental Health 2003;16(1):37-9.
173. Liu Y, Xu M, Chen X. A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms. Shandong Archires of Psychiatry 2004;17(1):6-8.
174. Liu Y, Xu M, Chen X. A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms. Shandong Archires of Psychiatry 2004;17(1):6-8.
175. Liu CX, Liu SH, Tu ZM, Liu B. A study of quetiapine with small doze of clozapine in treatment of resistant schizophrenia. Medical Journal of Chinese Peoplés Health 2005;17:748-9.
176. Liu H, Shi Y, Liu Z. A comparative study between quetiapine and risperidone in the treatment of schizophrenia. Journal of Heze Medical College 2005;17(1):15-6.
177. Liu Z, Han J, Cheng Y, Yan M, Zhou H. Study on quetiapine fumarate and risperidone in the treatment of schizophrenia. Journal of Hebei Medical College for Continuing Education 2006;23(2):14-6.
178. Liu B. Clinical study on quetiapine in treatment of refractory schizophrenia. China Modern Doctor 2007;45(18):24-5.
179. Liu L, Hou Z, Guo Y. A control study of quetiapine and risperidone in the treatment of elderly schizophrenia. Medical Journal of Chinese People's Health 2008;20(7):639-40.
180. Lu S, Zhang S-A, Ren Y. Comparative study on the psychopathology and the quality of life of schizophrenia treated with risperidone, clozapine and quetiapine. Journal of Nursing Science 2005;20(3):57-9.
181. Luo Y, Zhang S-W, Wang A-Q. The comparative study of quetiapine and clozapine in the treatment of female schizophrene. Medical Journal of Chinese People Health 2005;17(6):269-70.
182. Lv B, Wang J, Lin Y. A control study of quetiapine and risperidone in the treatment of eldly schizophrenia. Shandong Pharmacy 2008;48(16):91-2.
183. Mei Y, Pan J, Ma P, Pan G. Clinical observation on acute excitation of schizophrenia treated with quetiapine. Chinese Nursing Research 2006;20(5):1176-7.
184. Mintzer JE, Mullen JA, Sweitzer DE. A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. Current Medical Research and Opinion 2004;20(9):1483-91.
185. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clinical Therapeutics 2001;23(11):1839-54.
186. Musil RL, Spellmann I, Riedel M, Douhet A, Dehning S, Maino K, et al. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients treated with atypical antipsychotics. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S415.
187. Nai X, Hu X, Qiu W, Liu N, Wei H. Effect of quetiapine on cognitive function of patients with first episode schizophrenia. Journal of Medical Forum 2007;28(2):38-9.
188. Pan M, Wang H, Zhang S. A controlled study of domestic quetiapine and risperidone in the treatment of first-episode schizophrenia. Journal of Clinical Psychosomatic Diseases 2004;10(4):244-6.
189. Pan M, Zhang S-Q, Zhao Z. A comparative study of domestic quetiapine and risperidone in the treatment of schizophrenia. Medical Journal of Chinese Peoples Health 2004;16(10):597-8, 637.
190. Pan M, Zhang S, Zhao Z. Influence of three antipsychotic drugs on electrocardiogram in patients with schizophrenia. Journal of XinXiang Medical College 2004;21:403-4.
191. Pan W, Lin Z, Cheng B. A study of ziprasidone in the treatment of schizophrenia. Guide of China Medicine 2008;6(13):22-3.
192. Pang D, Wang C, Cui A. Effect of quetiapine fumarate and clozapine on clinical rehabilitation of schizophrenia:a controlled study. Chinese Journal of Clinical Rehabilitation 2002;6(7):1007.
193. Peng XX, Huang X. Control study of quetiapine on schizophrenia mainly with negative symptoms. Modern Journal of Integrated Traditional Chinese and Western Medicine 2004;13(12):1557-8.
194. Petty F. Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia. Clinical Trial Registration Data 2006.
195. Pfizer. Effect and Safety of Ziprasidone Compared to Other Atypical Antipsychotic Drug in Schizophrenic Patients. Clinical Trial Registration Data 2005.
196. Qi F, Wang L, Zhen Y. Comparison of efficacy and safety of quetiapine and risperidone in the treatment of schizophrenia. Shanghai Archives of Psychiatry 2004;16(2):78-9, 119.
197. Qian D, Pan B, Yang G. Cost-effectiveness analysis of 3 kinds of therapeutic schemes for schizophrenia. Evaluation and Analysis of Drug Use in Hospital of China 2004;4(2):110-1.
198. Reznik I, Slavkin L, Shabash E, Shaked G, Kertzman S, Spivak B, et al. Quetiapine ("Seroquel") and olanzapine for acute treatment of patients with schizophrenia: an open-label, comparative study. Proceedings of the XXIV Collegium Internationale Neuro-Psychopharmacologicum; Paris, France, June 20-24, 2004. 1-4.
199. Riera L, Tandon R, Stock EG, Kujawa MJ, Torbeyns AF, Borian FE. Broad effectiveness trial with aripiprazole. Proceedings of the Twelfth Biennial Winter Workshop on Schizophrenia, Davos, Switzerland, February 7-13, 2004.
200. Ruan J, Huang G. A control study of quetiapine and clozapine in the treatment of difficult-to-treat schizophrenia. Medical Journal of Chinese People's Health 2005;17(12):747-8.
201. Ryu SH, Jang WS, Cho EY, Kim SK, Lee DS, Hong KS. Association of leptin gene polymorphism with antipsychotic drug-induced weight gain. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S419.
202. Sajatovic M, Mullen JA, Sweitzer D. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychotic disorders. Proceedings of the 155th Annual Meeting of the American Psychiatric Association, Philadelphia, Pennsylvania, USA, May 18-23, 2002.
203. Sarma K. Lurasidone HCl - A Long Term Phase 3 Study ofPatients With Chronic Schizophrenia (PEARL 3Ext). Clinical Trial Registration Data 2008.
204. Sheng D, Yang Y. A study of cognitive function about quetiapine and clozapine in the treatment of schizophrenia. Journal of Clinical Psychological Medicine 2006;16(5):304.
205. Song F. A control study of quetiapine and clozapine in the treatment of schizophrenia. Health Horizon Medical Science Fascicule 2006;(7):91.
206. Song C, Wang H, Sun X. A control study of quetiapine and clozapine in the treatment of schizophrenia of quality of life. Journal of Clinical Psychological Medicine 2008;18(2):133-4.
207. Song G, Li Y. A control study of quetiapine and clozapine in the treatment of chronic schizophrenia. Medical Journal of Chinese People's Health 2008;20(23):2790.
208. Sun T, Liu H. A control study of quetiapine and clozapine in the treatment of children's first-episode schizophrenia. Shandong Archives of Psychiatry 2006;19(2):141-2.
209. Sun X, Zou S, Li Z, Han Z. Effect of cognitive function in first-episode schizophrenia treated with quetiapine. Journal of Clinical Psychological Medicine 2006;16(2):94-5.
210. Sun Q, Zeng D, Chen K. Clinical comparative study of ziprasidone in the treatment of schizophrenia. Journal of Psychiatry 2007;20(3):150-1.
211. Sun M, Liang F, Meng Y. A control study on quetiapine in gerontic first-episode schizophrenia. Journal of Chinese Psychosomatic Disorders 2007;13(5):407-8.
212. Sun L, Wang Y. A control study of quetiapine and clozapine in the treatment of schizophrenia. China Practical Medicine 2007;2(21):97.
213. Sun H, Jiao Y, Li J. A comparative study of quetiapine and risperidone in the treatment of old men with schizophrenia. Medical Journal of Chinese People's Health 2008;20(1):14-6.
214. Swadi HS, Craig BJ, Pirwani NZ, Black VC, Buchan JC, Bobier CM. A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15-to 18-year-old adolescents. International Clinical Psychopharmacology 2010;25(1):1-6.
215. Swanson JW, Swartz MS, Van Dorn RA. Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25, 2006.
216. Tang Y. A controlled study of schizophrenia treated with quetiapine and clozapine. Shanghai Archives of Psychiatry 2003;15(1):27-9.
217. Tang Z-K, Xu C-M, Chen D. A comparative study of quetiapine and clozapine in the treatment of recurrent schizophrenia. Shandong Archives of Psychiatry 2005;18(3):167-8.
218. Tao S, Chen Q, Yang C, Pan R, Pan T, Li L, Zhou W. A comparison of the effects on lipid metabolic among four different atypical antipsychotic agents. Journal of Youjiang Medical College 2008, (6):7-9.
219. Tian B, Li J, Jing H, Zhang W, Liu Y. A comparative study between seroquel and risperidone in the treatment of schizophrenia. Shandong Archives of Psychiatry 2006;19(1):25-6.
220. Tian C, Li Z. Control studies on the curative effect and influence of quetiapine and clozapine on quality of life of schizophrenics. J Clin Psychosom Disease 2007;13(2):133-4.
221. Tian H, Zhu Q. A comparative study of new antipsychopathic drugs lead to gain weight. Medical Journal of Chinese People's Health 2008;20(18):2119-20.
222. Wang M, Liu M, Lu L. A controlled study on seroquel and risperidone in the treatment of schizophrenic patients. Journal of Clinical Psychological Medicine 2000;10(4):200-1.
223. Wang X. Comparative study of effects of quetiapine and clozapine on quality of life of schizophrenics. Journal of Clinical Psychosomatic Diseases 2004;10(3):167-8.
224. Wang M, Han F, Ma H. Comparation of quetiapine and clozapine in treatment of patients with first-onset schizophrenia. Chinese Journal of Clinical Pharmacology and Therapeutics 2004;9(5):551-4.
225. Wang C-H, Li Y, Liu X. Cognitive function and p300 potentials in first-episode schizophrenia treated with quetiapine and risperidone. Chinese Mental Health Journal 2005;19(5):333-6.
226. Wang C-H, Li Y, Wang L-H, Pan M, ZHao Z, Mu J-L. Comparison of cognitive function and event related potentials in first episode schizophrenic treated with antipsychotic drugs. Journal of Clinical Psychological Medicine 2005;15(3):168-70.
227. Wang X, Yang J, Guo H. Clinical study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases 2005;11(2):118-9.
228. Wang X-F, Wang W-H, Wang J-C. Analysis of quetiapine in treatment of first-episode schizophrenia. Sichuan Mental Health 2005;18:235-6.
229. Wang Y, Sun M, Shao X. A comparative study between quetiapine and clozapine in the treatment of schizophrenia. Heath Psychology Journal 2005;13(4):271-2.
230. Wang D, Wang X. Comparative study of guetiapine and risperidone in the treatment of schizophrenia. Modern Medicine Health 2006;22(6):815-6.
231. Wang J, Ran R. Effects of quetiapine vs clozapine on the quality of life in first-episode schizophrenics. Journal of Clinical Psychosomatic Disorders 2006;12(6):416-7.
232. Wang C, Xu X, Huo X. A study of quetiapine and risperidone in treatment of chronic schizophrenia. Journal of Clinical Psychological Medicine 2007;17(4):165-6.
233. Wang H, Sun D, Zhang Z, Gao C. A control study of quetiapine and risperidone in the treatment of children's schizophrenia. Journal of Clinical Psychological Medicine 2007;17(3):199-200.
234. Wang Y, Chen T. Non-classical antipsychotic drugs for schizophrenia :cost minimization analysis on 3 schemes. China Pharmacy 2007;18(32):2487-8.
235. Wang J, Wu H. A comparative study of social function in schizophrenia patients treated with seroquel or clozapine. Medical Journal of Chinese People's Health 2008;20(11):1137-8.
236. Wang X, Song C. Comparative study of efficacy and safety of quetiapine and risperidone in the treatment of elderly schizophrenia. China Journal of Health Psychology 2008;16(12):1394-6.
237. Wang Y, Li G, Li T. Comparison on the efficacy of quetiapine and risperidone in the treatment of the depressive symptom of schizophrenia. Tianjin Pharmacy 2008;20(2):33-6.
238. Wang Y, Wang J. Effects of quetiapine on cognitive function in schizophrenia patients. China Practical Medicine 2008;3(18):61-2.
239. Wei S. A randomized, double blind double dummy parallel controlled study in the female first-onset schizophrenia treated with aripiprazole and quetiapine. Nervous Diseases and Mental Health 2006;6(3):194-7.
240. Wei S. A control study of quetiapine and clozapine in the treatment of eldly schizophrenia. Journal of Clinical Psychological Medicine 2006;16(1):43.
241. Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropyschopharmacology 2003;28(8):1491-500.
242. Wen S, Chen F. A control study of quetiapine and risperidone in the treatment of schizophrenia. Modern Medicine Health 2005;21(22):3089-90.
243. Wu Y, Wang X. A control study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Clinical Psychological Medicine 2005;15(2):106-7.
244. Xiang DF, Liu XL. Treatment of 31 cases of schizophrenia with quetiapine. Herald of Medicine 2005;24(1):40-2.
245. Xu MQ, Peng MY. A study of Quetiapine in treatment of schizophrenia. Journal of Clinical Psychology Medicine 2002;12:227-8.
246. Xu LZ, Ouyang JL, Gao SZ. Effects of domestic quetiapine vs clozapine in treatment of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies 2003;7477(9):542-5.
247. Xu XF, Zhang XB, Zhou CY, Dai XG. Comparison of efficacy and safety of seroquel and risperidone in the treatment of schizophrenia. Journal of Jiangsu Clinical Medicine 2005;9(1):20-2.
248. Xu B. Comparative observation on the efect of quetiapine fumarate on chronic schizoprenia patients. China Tropical Medicine 2006;6(6):1032.
249. Yamashita H, Mori K, Nagao M, Okamoto Y, Morinobu S, Yamawaki S. Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults. American Journal of Geriatric Psychiatry 2005;13(5):377-84.
250. Yang FS, Yang YL, Zhang ZH. Control study on quetiapine and clozapine in treatment of refractory schizophrenia. Medical Journal of Chinese People Health 2004;16(1):12-3.
251. Yang Q-P, Huang Y-P, Yang B-X. The effect of quetiapine and risperidone on the EEG of first-episode schizophrenic patients. Shandong Archives of Psychiatry 2005;18(3):159-60.
252. Yang Q-P, Huang Y-P, Yang B-X. The effect of quetiapine and risperidone on the EEG of first-episode schizophrenic patients. Shandong Archives of Psychiatry 2005;18(3):159-60.
253. Yang Y. Control study of quetiapine and clozapine in the treatment of refractory schizophrenia. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease 2006;14(4):276-7.
254. Yang M, Mu X, Zhao A. A clinical study of quetiapine associated with clonazepam in the treatment of schizophrenia. Journal of Qiqihar Medical College 2006;27(9):1034-5.
255. Yang C, Guo P, Guo H. Control study on using quetiapine to treat schizophrenic patients. China Practical Medicine 2006;1(1):24-6.
256. Yang K. Comparative study between the effect of risperidone and quetiapine in first-episode schizophrenia. Medical Journal of Chinese People's Health 2007;19(3):203-4.
257. Yang X, Wang Z, Lv Y, Shi Y. Comparative study of curative effects and influence on cognitive function of quetiapine and clozapine in schizophrenia. Journal of Clinical Psychosomatic Disorders 2007;13(1):29-30.
258. Yu G, Liang S, He Z-G. Comparison of quetiapine and clozapine in treatment of schizophrenia. Journal of Clinical Psychiatry Medicine 2003;25:4-5.
259. Yu H, Kong H. A control study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Clinical Psychological Medicine 2005;15(6):362.
260. Yu W, Liu H, Pan S. A control study of quetiapine and loxapine in the treatment of schizophrenia. Journal of Clinical Psychological Medicine 2006;16(5):298.
261. Yuan F-J, Gao M-Z, Liu X. A contrast observation of quetiapine and clozapine in affecting electroencephalogram. Journal of Practical Medical Techniques 2005;12(2B):482-4.
262. Zeng J. A control study of quetiapine and aripiprazole in the treatment of children's schizophrenia. Journal of Clinical Psychological Medicine 2006;16(6):367.
263. Zhang L, Wu Y, Guo C. A comparative study between quetiapine and risperidone in the treatment of schizophrenia. Health Psychology Journal 2003;11(4):262-3.
264. Zhang M, Zhang H-F, Gu W. A comparative study of quetiapine and clozapine in the treatment of schizophrenia. Shandong Archives of Psychiatry 2005;18(2):86-8.
265. Zhang H, Zhang M, Gu W. A comparative study of social function in schizophrenia patients treated with seroquel (quetiapine) or clozapine. Sichuan Mental Health 2005;18(2):91-3.
266. Zhang R-X, Cao Y-F. A comparative study of EKG changed by quetiapine and clozapine in the treatment of schizophrenia. Medical Journal of Chinese People Health 2005;17(6):290-1.
267. Zhang Y, Jiang Y, Zhao S. A comparative study of quetiapine combined with clomipramine in treatment of schizophrenia with obsessive-compulsive symptoms. Chinese Journal of Health Psychology 2005;13(4):260-2.
268. Zhang W, Ma J, Ma L. A control study of quetiapine and risperidone in the treatment of first-episode schizophrenia. Chinese Journal of Current Traditional and Western Medicine 2005;3(12):1088-9.
269. Zhang w, Ma J, Xu F. Comparison study on treatment of primary schizophrenia with quetiapine and chlorpromazine. Heilongjiang Medical Journal 2006;30(2):81-2.
270. Zhang Y, Zhou B. A control study of quetiapine and clozapine in the treatment of schizophrenia. Journal of Clinical Psychological Medicine 2006;16(5):300.
271. Zhang C. A control study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Clinical Psychological Medicine 2007;17(3):197-8.
272. Zhang L. A comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia. Modern Medicine Journal of China 2007;9(2):97-8.
273. Zhang B. Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (SeroquelIR) in Controlling Agitation and AggressiveSymptoms in the Acute Treatment of Patients With Schizophrenia. WHO trial registration 2009; Vol. 2.
274. Zhao F, Zhang Z, Li H. Control studies of quetiapine and risperidone in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases 2004;10(1):25-6.
275. Zhao L, Li Y, Qi F. Control study of quetiapine and risperidone in treatment of schizophrenics. Heath Psychology Journal 2005;13(1):56, 79-80.
276. Zhao YH, Fang JH, Wang SH, An CG, Ma X, Li HX. A study of quetiapine and clozapine in treatment of schizophrenia. Journal of Clinical Psychology Medicine 2005;15:231-2.
277. Zhao L, Gong GQ. A study of low-dos equetiapine with sulpiride in the treatment of schizophrenia. Journal of Clinical Research 2007;24(7):1181-2.
278. Zheng J, Wang B, Fu A, Li P. A control study of quetiapine and clozapine in the treatment of schizophrenia. Medical Recapitulate 2007;13(23):1878-9.
279. Zhong Z-Y, Tao J, Wang X-L, Wu X-L, Zhang J-B. Effect of antipsychotic plus buflomedil hydrochlorde in ameliorating the negative symptoms of patients with schizophrenia. Zhongguo Linchuang Kangfu 2006;10(2):30-2.
280. Zhou P, Gong F, Fan C. A control of treating chronic schizophrenia with seroquel or clozapine. Jiangxi Medical Journal 2003;38(6):395-6.
281. Zhou R, Dai X. A comparative study of quetiapine and clozapine in the treatment of patients with schizophrenia. Shanghai Archives of Psychiatry 2003;15(4):215-7.
282. Zhou M. A study of quetiapine with sulpiride in the treatment of chronic schizophrenia. Journal of Clinical Psychological Medicine 2006;16(6):368.
283. Zhou B, Zhang Y. A control study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Baotou Medical College 2007;23(3):261-2.
284. Zhu Q, Zhang S. A control study of quetiapine and clozapine in the treatment of female schizophrenia. Herald of Medicine 2006;25(8):792-3.
285. Zhu M, Pan D, Lu S. A control study of quetiapine and aripiprozole in the treatment of schizophrenia. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine 2008;8(1):9-10.
286. Gafoor R, Landau S, Craig TKH, Elanjithara T, Power P, McGuire P. Efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. Journal of Clinical Psychopharmacology 2010;30:600-6.
287. Gafoor R, Power P, Craig T, Kerwin R, McGuire P. A comparative study of quetiapine and risperidone in patients with first-episode psychosis. Journal of the European College of Neuropsychopharmacology 2005;15(Suppl 3):S509.
288. Eli Lilly, Company. Comparison of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder. Eli Lilly and Company Clinical Trial Registry 2004. [8894]
289. Li HF. A 6-Week, Multicenter, Rater-Blind, Randomized, Risperidone-Controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia. WHO registration 2009; Vol. 1.
290. Ratna L. A multi-centre, double-blind, randomised study to compare the safety tolerability and efficacy of quetiapine and risperidone in the treatment of schizophrenia in subjects with inadequate symptom control improved Response In Schizophrenia - IRIS. National Research Register 2003; Vol. 1.
291. Reynolds C. A six month, rater blind comparison of quetiapine and risperidone in the treatment of tardive dyskinesia in patients with schizophrenia. National Research Register 2001; Vol. 3.
292. Allebeck P, Varla A, Wistedt B. Suicide and violent death among patients with schizophrenia. Acta Psychiatrica Scandinavia 1986;74(1):43-9.
293. Altman DG, Bland JM. Detecing skewness from summary information. BMJ 1996;313:1200.
294. Andreasen NC. Scale for the assessment of positive symptoms (SAPS). The University of Iowa 1984.
295. Andreasen NC. Scale for the assessment of negative symptoms (SANS). British Journal of Psychiatry 1989;7:53-8.
296. Andreasen NC. Assessment issues and the cost of schizophrenia. Schizophrenia Bulletin 1991;17:408-10.
297. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry. 2nd Edition. American Journal of Psychiatry, 2004:1-114.
298. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101.
299. Barnes TR. A rating scale for drug induced akathisia. British Journal of Psychiatry 1989;154:672-6.
300. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
301. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
302. Heinrichs DW, Hanlon ET, Carpenter WT Jr. The quality of life scale: an instrument for rating the schizophrenic deficit syndrom. Schizophrenia Bulletin 1984;10:388-96.
303. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
304. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The extrapyramidal symptom rating scale. Canadian Journal of Neurological Sciences 1980;7:233.
305. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium, Cape Town, South Africa, October 25-28, 2000.
306. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
307. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
308. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: APA, 1994.
309. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2]
310. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
311. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004578.pub3]
312. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
313. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
314. Gaebel W, Falkai P, Weinmann S, Wobrock T. Treatment guidelines for schizophrenia [Behandlungsleitlinie Schizophrenie]. Steinkopf 2006.
315. Goldstein JM, Litwin LC, Sutton EM, Malick JB. Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 1993;112:293-8.
316. Goldstein JM. Preclinical tests that predict clozapine-like atypical antipsychotic actions. Critical issues in the treatment of schizophrenia. International Academy of biochemical Drug Research 1995;10:95-101.
317. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
318. Guy U. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health, 1976.
319. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry 2006;163:185-94.
320. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
321. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008] The Cochrane Collaboration, 2008. www.cochrane-handbook.org.
322. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
323. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
324. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life. Archives of General Psychiatry 2006;63:1079-6.
325. Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group. Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789-96.
326. Kane JM. Treatment programme and long term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica 1993;46:585-93.
327. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi-Health Systems, 1986.
328. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
329. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores (BPRSS). British Journal of Psychiatry 2005;187:366-71.
330. Liebermann JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209-23.
331. Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
332. Marvaha S, Johnson S. Schizophrenia and employment - a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337-49.
333. Migler BM, Warawa EJ, Malick JB. Seroquel: behavioral profile of a potential atypical antipsychotic. Psychopharmacology 1993;112:299-307.
334. Moher D, Schulz KF, Altman D. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 2001;285:1987-1.
335. Moller HJ. New assessment of atypical antipsychotics [Aktuelle Bewertung neuer/atypischer Neuroleptika]. Nervenarzt 2000;71:329-44.
336. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004;363(9426):2063-72.
337. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
338. Rust J, Golombok S. Modern Psychometrics. London: Routledge, 1989.
339. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993;112:285-92.
340. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
341. Simpson EN, Angus JWF. A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica Supplementum 1970;212:11-9.
342. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: CD000967]
343. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology 2009;62(5):464-75. [PUBMED: 19348971]
344. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):3-92.
345. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H. The Leeds Outcomes Stakeholders Survey (LOSS) study. Proceedings of the 15th Cochrane Colloquium, Sao Paulo, October 23-27, 2007.
346. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, Kissling W, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: DOI:10.1002/14651858.CD006625.pub2.]
347. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 2009;166:152-63. [DOI: 10.1176/appi.ajp.2008.08030368]
348. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue Issue 2. [DOI: 10.1002/14651858.CD000967.pub2]